Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
MorphoSys AG currently has 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 6 distinct examiners and 6 distinct art units. PO-CHIH CHEN is the busiest examiner, currently responsible for 1 pending action. The presence of 6 pending actions indicates a steady level of engagement with the USPTO in the pharmaceutical sector.
The distribution of actions across 6 distinct examiners and 6 distinct art units suggests a highly diversified prosecution profile. Each of the 6 pending office actions is being reviewed by a different examiner, ensuring a variety of perspectives on the company's technology. PO-CHIH CHEN's 1 pending action is part of this broader, non-overlapping strategy. Because each action is in a different art unit, the company's biotech innovations likely span several distinct technical categories within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §102 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019634 | 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE FOR TREATING THROMBOCYTHEMIA | WEBB, WALTER E | 37d overdue |
| 18289467 | MODULATORS OF TREX1 | RAO, PADMAJA S | 18d overdue |
| 18987624 | SYNTHESIS OF BROMODOMAIN INHIBITORS | CHEN, PO-CHIH | — |
| 18290181 | USE OF PELABRESIB FOR TREATING ANEMIAS | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1626 | 1 |
| 1624 | 1 |
| 1629 | 1 |
| 1627 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18987624 | SYNTHESIS OF BROMODOMAIN INHIBITORS | CHEN, PO-CHIH | 1621 | §102 | Non-Final OA | — | Pending | Dec 19, 2024 |
| 18938453 | MODULATORS OF TREX1 | JACKSON, SHAWQUIA | 1626 | DP | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18834256 | ANHYDROUS CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE | SAMSELL, RILLA MARIE | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18290181 | USE OF PELABRESIB FOR TREATING ANEMIAS | SEITZ, ANTHONY JOSEPH | 1629 | §103 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18289467 | MODULATORS OF TREX1 | RAO, PADMAJA S | 1627 | DP | Final Rejection | 18d overdue | Pending | Nov 03, 2023 |
| 18019634 | 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE FOR TREATING THROMBOCYTHEMIA | WEBB, WALTER E | 1612 | §103DP | Non-Final OA | 37d overdue | Pending | Feb 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMorphoSys AG has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Po-Chih Chen has the most, with 1 of MorphoSys AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
